Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

ClinicalTrials.gov ID: NCT01338818

Public ClinicalTrials.gov record NCT01338818. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the long-term safety of methylphenidate hydrochloride extended release in adults with attention deficit/hyperactivity disorder

Study identification

NCT ID
NCT01338818
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
299 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 60 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 2011 (Type not available)
Primary completion
Feb 2013 (Actual)
Completion
Feb 2013 (Actual)
Last update posted
Nov 24, 2014

2011 – 2013

United States locations

U.S. sites
16
U.S. states
11
U.S. cities
15
Facility City State ZIP Site status
Novartis Investigative Site Little Rock Arkansas 72205 —
Novartis Investigative Site Beverly Hills California 90210 —
Novartis Investigative Site Spring Valley California 91978-1522 —
Novartis Investigative Site Bradenton Florida 34208 —
Novartis Investigative Site Orlando Florida 32806 —
Novartis Investigative Site West Plam Beach Florida 33407 —
Novartis Investigative Site Libertyville Illinois 60048 —
Novartis Investigative Site Owensboro Kentucky 42301 —
Novartis Investigative Site Las Vegas Nevada 89119 —
Novartis Investigative Site Las Vegas Nevada 89128 —
Novartis Investigative Site Fargo North Dakota 58103 —
Novartis Investigative Site Columbus Ohio 43210 —
Novartis Investigative Site Philadelphia Pennsylvania 19149 —
Novartis Investigative Site Houston Texas 77007 —
Novartis Investigative Site Bellevue Washington 98004 —
Novartis Investigative Site Seattle Washington 98104 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01338818, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 24, 2014 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01338818 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →